Status:
UNKNOWN
Focused Stereotactic Radiation Treatment of Prostatic Adenocarcinoma
Lead Sponsor:
Centre Francois Baclesse, Luxembourg
Conditions:
Prostate Cancer
Eligibility:
MALE
Brief Summary
Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure.
Detailed Description
Focused stereotactic radiation treatment of localized prostatic adenocarcinoma. in order to quantify the delay between the focused treatment and the salvage procedure. Second objectives : objectives:...
Eligibility Criteria
Inclusion
- Prostatic adenocarcinoma of Capra score≤2 invading no more than two adjacent of the 12 prostatic zones. Lesions\>3mm. Maximal urinary flow rate ≥ 10ml/s, mean flow rate ≥ 5ml/s, post micturation volume ≤80ml, IPSS score ≤15.
Exclusion
- systemic disease, ulcerative hemorrhagic ulcer or Crohn diseases, bladder neck stenosis, urethral implants, transurethral prostatectomy (TURP), any recurrent prostatitis within the last 3 years.
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2023
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03284151
Start Date
January 1 2015
End Date
January 1 2023
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre Francois Baclesse
Esch-sur-Alzette, Luxembourg, 4005